Renaissance Technologies’s Blueprint Medicines BPMC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-674,500
Closed -$86.5M 3518
2025
Q2
$86.5M Buy
+674,500
New +$70.1M 0.12% 187
2025
Q1
Sell
-126,300
Closed -$11M 3480
2024
Q4
$11M Sell
126,300
-48,200
-28% -$4.42M 0.02% 958
2024
Q3
$16.1M Buy
174,500
+64,100
+58% +$6.37M 0.02% 790
2024
Q2
$11.9M Buy
110,400
+62,900
+132% +$6.3M 0.02% 823
2024
Q1
$4.51M Buy
+47,500
New +$4.07M 0.01% 1486
2023
Q1
Sell
-85,400
Closed -$3.74M 3989
2022
Q4
$3.74M Buy
+85,400
New +$4.1M 0.01% 1688
2022
Q2
Sell
-68,400
Closed -$4.37M 4230
2022
Q1
$4.37M Buy
+68,400
New +$4.91M 0.01% 1696
2021
Q3
Sell
-152,374
Closed -$13.4M 3487
2021
Q2
$13.4M Sell
152,374
-47,026
-24% -$4.31M 0.02% 991
2021
Q1
$19.4M Sell
199,400
-82,500
-29% -$8.24M 0.02% 790
2020
Q4
$31.6M Buy
281,900
+96,700
+52% +$10.2M 0.03% 533
2020
Q3
$17.2M Buy
185,200
+125,500
+210% +$9.66M 0.02% 811
2020
Q2
$4.66M Sell
59,700
-49,500
-45% -$3.35M ﹤0.01% 1687
2020
Q1
$6.39M Buy
+109,200
New +$7.03M 0.01% 1423
2018
Q3
Sell
-245,800
Closed -$15.6M 3354
2018
Q2
$15.6M Buy
+245,800
New +$19.6M 0.02% 1083
2017
Q3
Sell
-13,000
Closed -$659K 3208
2017
Q2
$659K Sell
13,000
-24,400
-65% -$1.04M ﹤0.01% 2689
2017
Q1
$1.5M Buy
37,400
+26,900
+256% +$963K ﹤0.01% 2376
2016
Q4
$295K Sell
10,500
-700
-6% -$21.1K ﹤0.01% 2914
2016
Q3
$333K Buy
+11,200
New +$278K ﹤0.01% 2931

Other funds holding BPMC

Renaissance Technologies's BPMC Position: Q3 2025 in Review

Renaissance Technologies sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 674,500 shares — an estimated $86.5M sold.

Renaissance Technologies first reported a position in BPMC in Q3 2016 and held it in 18 quarters. The position peaked at $86.5M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Renaissance Technologies reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Renaissance Technologies sold 674,500 Blueprint Medicines shares in Q3 2025, an estimated $86.5M.
  • Renaissance Technologies first reported a position in Blueprint Medicines in Q3 2016 and held it in 18 quarters.
  • Renaissance Technologies's Blueprint Medicines position peaked at $86.5M in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Renaissance Technologies's 13F filing for Q3 2025, filed 13 Nov 2025.